2016-07899. Endocrinologic and Metabolic Drugs Advisory Committee; Amendment of Notice

AGENCY:

Food and Drug Administration, HHS.

ACTION:

Notice.

SUMMARY:

The Food and Drug Administration (FDA) is announcing an amendment to the notice of a meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. This meeting was announced in the Federal Register of March 16, 2016. The amendment is being made to reflect a change in the Date and Time portion of the document. The Date of the meeting is changed to May 25, 2016. There are no other changes.

FOR FURTHER INFORMATION CONTACT:

LaToya Bonner, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 31, Rm. 2417, Silver Spring, MD 20993-0002, 301-796-9001, FAX: [phone], [e-mail], or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area). Please call the Information Line for up-to-date information on this meeting.

SUPPLEMENTARY INFORMATION:

In the Federal Register of March 16, 2016 (81 FR 14115), FDA announced that a meeting of the Endocrinologic and Metabolic Drugs Advisory Committee would be held on May 24, 2016. On page 14115, in the second column, the Date and Time portion of the document is changed to read as follows:

Date and Time: The meeting will be held on May 25, 2016, from 8 a.m. to 5 p.m.

This notice is issued under the Federal Advisory Committee Act (5 U.S.C. app. 2) and 21 CFR part 14, relating to the advisory committees.

Dated: April 1, 2016.

Jill Hartzler Warner,

Associate Commissioner for Special Medical Programs.